ID

34480

Description

Periperal Blood Lymphocytes During Prostate RT; ODM derived from: https://clinicaltrials.gov/show/NCT01899391

Lien

https://clinicaltrials.gov/show/NCT01899391

Mots-clés

  1. 17/01/2019 17/01/2019 -
  2. 22/05/2019 22/05/2019 -
Détendeur de droits

see on clinicaltrials.gov

Téléchargé le

17 janvier 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Prostate Cancer NCT01899391

Eligibility Prostate Cancer NCT01899391

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
intermediate-risk prostate cancer patients (t1/t2n0m0 with either gs < 7 and psa between 10-20 ng/ml or gs 7 and psa less than 20 ng/ml).
Description

ID.1

Type de données

boolean

planned for radical rt to the prostate with imrt planning (79gy/39fractions or 60 gy/20 fractions).
Description

ID.2

Type de données

boolean

no contraindications to diagnostic ct scanning.
Description

ID.3

Type de données

boolean

prostate volumes will be less than 80 cc to control the planning dose volume histogram (dvh) as much as possible in terms of rectal and bladder volumes.
Description

ID.4

Type de données

boolean

no known dna repair disorders (e.g. family history of at, brca1/2 or li fraumeni syndrome) or contraindications to radical pelvic rt.
Description

ID.5

Type de données

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
inability to provide informed consent.
Description

ID.6

Type de données

boolean

patient having contraindications to diagnostic ct scan.
Description

ID.7

Type de données

boolean

patients who have unobtainable data regarding previous therapy and their clinical outcome.
Description

ID.8

Type de données

boolean

patients should not have any diagnostic x-rays or cat scans 2 weeks prior to their enrollment into the study.
Description

ID.9

Type de données

boolean

Similar models

Eligibility Prostate Cancer NCT01899391

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
intermediate-risk prostate cancer patients (t1/t2n0m0 with either gs < 7 and psa between 10-20 ng/ml or gs 7 and psa less than 20 ng/ml).
boolean
ID.2
Item
planned for radical rt to the prostate with imrt planning (79gy/39fractions or 60 gy/20 fractions).
boolean
ID.3
Item
no contraindications to diagnostic ct scanning.
boolean
ID.4
Item
prostate volumes will be less than 80 cc to control the planning dose volume histogram (dvh) as much as possible in terms of rectal and bladder volumes.
boolean
ID.5
Item
no known dna repair disorders (e.g. family history of at, brca1/2 or li fraumeni syndrome) or contraindications to radical pelvic rt.
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
inability to provide informed consent.
boolean
ID.7
Item
patient having contraindications to diagnostic ct scan.
boolean
ID.8
Item
patients who have unobtainable data regarding previous therapy and their clinical outcome.
boolean
ID.9
Item
patients should not have any diagnostic x-rays or cat scans 2 weeks prior to their enrollment into the study.
boolean

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial